There are 2949 resources available
1586MO - Pivotal trial endpoints of drugs for rare and non-rare cancers in the US and Europe
Presenter: Kerstin Vokinger
Session: Mini Oral - Public policy
Resources:
Abstract
Slides
Webcast
1587MO - How much does it cost to research and develop a new medicine? A systematic review and evaluation of 40 years of literature
Presenter: Karla Hernandez Villafuerte
Session: Mini Oral - Public policy
Resources:
Abstract
Slides
Webcast
1588MO_PR - A comparative study on costs of cancer and access to medicines in Europe
Presenter: Nils Wilking
Session: Mini Oral - Public policy
Resources:
Abstract
Slides
Webcast
1589MO - Opposition to a patent covering tisagenlecleucel: Using intellectual property (IP) legislation to defend sustainable access to cancer therapies
Presenter: Juliana Veras
Session: Mini Oral - Public policy
Resources:
Abstract
Slides
Webcast
1590MO - Income loss after a cancer diagnosis from the patient perspective: An analysis based upon the German Socio-Economic Panel (SOEP) survey
Presenter: Diego Hernandez
Session: Mini Oral - Public policy
Resources:
Abstract
Slides
Webcast
LBA26 - Phase II study of the oral HIF-2α inhibitor MK-6482 for Von Hippel-Lindau (VHL) disease-associated clear cell renal cell carcinoma (ccRCC): Update on RCC and non-RCC disease
Presenter: Ramaprasad Srinivasan
Session: Mini Oral - Genitourinary tumours, non-prostate
Resources:
Abstract
Slides
Webcast
703MO - An integrated study of spatial dynamics and genomic alterations in renal cell carcinoma evolution
Presenter: Yue Zhao
Session: Mini Oral - Genitourinary tumours, non-prostate
Resources:
Abstract
Slides
Webcast
LBA59 - First-line nivolumab (NIVO) + ipilimumab (IPI) combined with 2 cycles of platinum-based chemotherapy (chemo) vs 4 cycles of chemo in advanced non-small cell lung cancer (NSCLC): Patient-reported outcomes (PROs) from CheckMate 9LA
Presenter: Martin Reck
Session: Mini Oral - NSCLC, metastatic
Resources:
Abstract
Slides
Webcast
LBA60 - ZENITH20, a multinational, multi-cohort phase II study of poziotinib in NSCLC patients with EGFR or HER2 exon 20 insertion mutations
Presenter: Mark Socinski
Session: Mini Oral - NSCLC, metastatic
Resources:
Abstract
Slides
Webcast
LBA61 - First analysis of RAIN-701: Study of tarloxotinib in patients with non-small cell lung cancer (NSCLC) EGFR Exon 20 insertion, HER2-activating mutations & other solid tumours with NRG1/ERBB gene fusions
Presenter: Stephen Liu
Session: Mini Oral - NSCLC, metastatic
Resources:
Abstract
Slides
Webcast